Lloyd Segal

Lloyd M. Segal is the President and CEO of Repare Therapeutics (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to discovering and developing novel cancer therapeutics. Prior to Repare, Lloyd was a Managing Partner with Persistence Capital Partners, Canada’s leading healthcare private equity investor. Lloyd began his professional career as an associate with McKinsey & Company, and subsequently served as chief executive officer of several emerging biotechnology companies including Advanced Bioconcept Inc. (sold to Perkin-Elmer), Caprion Pharmaceuticals Inc. (now Caprion Biosciences), which he co-founded, and Thallion Pharmaceuticals Inc. He currently serves as a member of the board of directors of GBC American Fund, a U.S. growth-focused mutual fund. Lloyd also previously served as Chairman of LMC Diabetes & Endocrinology, North America’s leading community endocrinology clinical group, and was Chairman of the Board of MedReleaf (TMX:LEAF), which was sold to Aurora Cannabis for $3.2 billion in 2018. He served as Entrepreneur-in-Residence with Versant Ventures from 2016 to 2020. Lloyd was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies and also previously served on the boards of directors of several public (NYSE, Nasdaq and TMX) and private U.S. and Canadian companies. Lloyd holds a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.